Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions: A Subanalysis of the International, Multicenter GHOST-EU Registry

Salvatore Geraci, H Kawamoto, G Caramanno, N Ruparelia, D Capodanno, S Brugaletta, T Gori, H Nef, M Sabate, J Mehilli, M Lesiak, C Naber, Carlo Di Mario, P Capranzano, J Wiebe, A Araszkiewicz, S Pyxaras, A Mattesini, T Münzel, C TamburinoA Colombo, A Latib

Research output: Contribution to journalArticle

Abstract

Objectives The authors sought to investigate 1-year outcomes in patients treated with bioresorbable everolimus-eluting vascular scaffolds (BVS) for “long coronary lesions.” Background The present substudy derived from the GHOST-EU registry included 1,722 lesions in 1,468 consecutive patients, enrolled between November 2011 and September 2014 at 11 European centers. Methods The lesions were divided into 3 groups according to continuous BVS length: 1) shorter than 30 mm; 2) between 30 and 60 mm; and 3) longer than 60 mm. Primary device-oriented endpoint (target lesion failure [TLF]) was defined as a combination of cardiovascular death, target vessel myocardial infarction, or clinically driven target lesion revascularization. Results Patients with lesions ≥60 mm had more comorbidities and more complex lesion characteristics, including chronic total occlusions (37%), bifurcation lesions (40.3%), higher Syntax score (16.4 ± 7.8), and higher number of scaffolds implanted per lesion (3.3 ± 0.9 mm). The main target vessel was the left anterior coronary artery in all groups. Median follow-up was 384 (interquartile range: 359 to 459) days. One-year follow-up was completed in 70.3% of patients. TLF at 1 year was significantly higher in group C (group A 4.8%, group B 4.5%, group C 14.3%; overall p = 0.001), whereas there were no significant differences between groups A and B. Finally, a numerically higher (but not statistically significant) number of scaffold thromboses were observed in group C when compared with shorter lesions (group A 2.1%, group B 1.1%, group C 3.8%; overall p = 0.29). Conclusions In a real-world setting, treatment of long coronary lesions with BVS ≥60 mm was associated with a higher TLF rate, driven by myocardial infarction and clinically driven target lesion revascularization. © 2017
Original languageEnglish
Pages (from-to)560-568
Number of pages9
JournalJACC: Cardiovascular Interventions
Volume10
Issue number6
DOIs
Publication statusPublished - 2017

Fingerprint

Blood Vessels
Myocardial Infarction
Registries
Comorbidity
Coronary Vessels
Thrombosis
Equipment and Supplies
Everolimus
Therapeutics

Cite this

Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions: A Subanalysis of the International, Multicenter GHOST-EU Registry. / Geraci, Salvatore; Kawamoto, H; Caramanno, G; Ruparelia, N; Capodanno, D; Brugaletta, S; Gori, T; Nef, H; Sabate, M; Mehilli, J; Lesiak, M; Naber, C; Mario, Carlo Di; Capranzano, P; Wiebe, J; Araszkiewicz, A; Pyxaras, S; Mattesini, A; Münzel, T; Tamburino, C; Colombo, A; Latib, A.

In: JACC: Cardiovascular Interventions, Vol. 10, No. 6, 2017, p. 560-568.

Research output: Contribution to journalArticle

Geraci, S, Kawamoto, H, Caramanno, G, Ruparelia, N, Capodanno, D, Brugaletta, S, Gori, T, Nef, H, Sabate, M, Mehilli, J, Lesiak, M, Naber, C, Mario, CD, Capranzano, P, Wiebe, J, Araszkiewicz, A, Pyxaras, S, Mattesini, A, Münzel, T, Tamburino, C, Colombo, A & Latib, A 2017, 'Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions: A Subanalysis of the International, Multicenter GHOST-EU Registry', JACC: Cardiovascular Interventions, vol. 10, no. 6, pp. 560-568. https://doi.org/10.1016/j.jcin.2016.12.013
Geraci, Salvatore ; Kawamoto, H ; Caramanno, G ; Ruparelia, N ; Capodanno, D ; Brugaletta, S ; Gori, T ; Nef, H ; Sabate, M ; Mehilli, J ; Lesiak, M ; Naber, C ; Mario, Carlo Di ; Capranzano, P ; Wiebe, J ; Araszkiewicz, A ; Pyxaras, S ; Mattesini, A ; Münzel, T ; Tamburino, C ; Colombo, A ; Latib, A. / Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions: A Subanalysis of the International, Multicenter GHOST-EU Registry. In: JACC: Cardiovascular Interventions. 2017 ; Vol. 10, No. 6. pp. 560-568.
@article{6189164cd23943899cf2075abad55a10,
title = "Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions: A Subanalysis of the International, Multicenter GHOST-EU Registry",
abstract = "Objectives The authors sought to investigate 1-year outcomes in patients treated with bioresorbable everolimus-eluting vascular scaffolds (BVS) for “long coronary lesions.” Background The present substudy derived from the GHOST-EU registry included 1,722 lesions in 1,468 consecutive patients, enrolled between November 2011 and September 2014 at 11 European centers. Methods The lesions were divided into 3 groups according to continuous BVS length: 1) shorter than 30 mm; 2) between 30 and 60 mm; and 3) longer than 60 mm. Primary device-oriented endpoint (target lesion failure [TLF]) was defined as a combination of cardiovascular death, target vessel myocardial infarction, or clinically driven target lesion revascularization. Results Patients with lesions ≥60 mm had more comorbidities and more complex lesion characteristics, including chronic total occlusions (37{\%}), bifurcation lesions (40.3{\%}), higher Syntax score (16.4 ± 7.8), and higher number of scaffolds implanted per lesion (3.3 ± 0.9 mm). The main target vessel was the left anterior coronary artery in all groups. Median follow-up was 384 (interquartile range: 359 to 459) days. One-year follow-up was completed in 70.3{\%} of patients. TLF at 1 year was significantly higher in group C (group A 4.8{\%}, group B 4.5{\%}, group C 14.3{\%}; overall p = 0.001), whereas there were no significant differences between groups A and B. Finally, a numerically higher (but not statistically significant) number of scaffold thromboses were observed in group C when compared with shorter lesions (group A 2.1{\%}, group B 1.1{\%}, group C 3.8{\%}; overall p = 0.29). Conclusions In a real-world setting, treatment of long coronary lesions with BVS ≥60 mm was associated with a higher TLF rate, driven by myocardial infarction and clinically driven target lesion revascularization. {\circledC} 2017",
author = "Salvatore Geraci and H Kawamoto and G Caramanno and N Ruparelia and D Capodanno and S Brugaletta and T Gori and H Nef and M Sabate and J Mehilli and M Lesiak and C Naber and Mario, {Carlo Di} and P Capranzano and J Wiebe and A Araszkiewicz and S Pyxaras and A Mattesini and T M{\"u}nzel and C Tamburino and A Colombo and A Latib",
year = "2017",
doi = "10.1016/j.jcin.2016.12.013",
language = "English",
volume = "10",
pages = "560--568",
journal = "JACC: Cardiovascular Interventions",
issn = "1936-8798",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions: A Subanalysis of the International, Multicenter GHOST-EU Registry

AU - Geraci, Salvatore

AU - Kawamoto, H

AU - Caramanno, G

AU - Ruparelia, N

AU - Capodanno, D

AU - Brugaletta, S

AU - Gori, T

AU - Nef, H

AU - Sabate, M

AU - Mehilli, J

AU - Lesiak, M

AU - Naber, C

AU - Mario, Carlo Di

AU - Capranzano, P

AU - Wiebe, J

AU - Araszkiewicz, A

AU - Pyxaras, S

AU - Mattesini, A

AU - Münzel, T

AU - Tamburino, C

AU - Colombo, A

AU - Latib, A

PY - 2017

Y1 - 2017

N2 - Objectives The authors sought to investigate 1-year outcomes in patients treated with bioresorbable everolimus-eluting vascular scaffolds (BVS) for “long coronary lesions.” Background The present substudy derived from the GHOST-EU registry included 1,722 lesions in 1,468 consecutive patients, enrolled between November 2011 and September 2014 at 11 European centers. Methods The lesions were divided into 3 groups according to continuous BVS length: 1) shorter than 30 mm; 2) between 30 and 60 mm; and 3) longer than 60 mm. Primary device-oriented endpoint (target lesion failure [TLF]) was defined as a combination of cardiovascular death, target vessel myocardial infarction, or clinically driven target lesion revascularization. Results Patients with lesions ≥60 mm had more comorbidities and more complex lesion characteristics, including chronic total occlusions (37%), bifurcation lesions (40.3%), higher Syntax score (16.4 ± 7.8), and higher number of scaffolds implanted per lesion (3.3 ± 0.9 mm). The main target vessel was the left anterior coronary artery in all groups. Median follow-up was 384 (interquartile range: 359 to 459) days. One-year follow-up was completed in 70.3% of patients. TLF at 1 year was significantly higher in group C (group A 4.8%, group B 4.5%, group C 14.3%; overall p = 0.001), whereas there were no significant differences between groups A and B. Finally, a numerically higher (but not statistically significant) number of scaffold thromboses were observed in group C when compared with shorter lesions (group A 2.1%, group B 1.1%, group C 3.8%; overall p = 0.29). Conclusions In a real-world setting, treatment of long coronary lesions with BVS ≥60 mm was associated with a higher TLF rate, driven by myocardial infarction and clinically driven target lesion revascularization. © 2017

AB - Objectives The authors sought to investigate 1-year outcomes in patients treated with bioresorbable everolimus-eluting vascular scaffolds (BVS) for “long coronary lesions.” Background The present substudy derived from the GHOST-EU registry included 1,722 lesions in 1,468 consecutive patients, enrolled between November 2011 and September 2014 at 11 European centers. Methods The lesions were divided into 3 groups according to continuous BVS length: 1) shorter than 30 mm; 2) between 30 and 60 mm; and 3) longer than 60 mm. Primary device-oriented endpoint (target lesion failure [TLF]) was defined as a combination of cardiovascular death, target vessel myocardial infarction, or clinically driven target lesion revascularization. Results Patients with lesions ≥60 mm had more comorbidities and more complex lesion characteristics, including chronic total occlusions (37%), bifurcation lesions (40.3%), higher Syntax score (16.4 ± 7.8), and higher number of scaffolds implanted per lesion (3.3 ± 0.9 mm). The main target vessel was the left anterior coronary artery in all groups. Median follow-up was 384 (interquartile range: 359 to 459) days. One-year follow-up was completed in 70.3% of patients. TLF at 1 year was significantly higher in group C (group A 4.8%, group B 4.5%, group C 14.3%; overall p = 0.001), whereas there were no significant differences between groups A and B. Finally, a numerically higher (but not statistically significant) number of scaffold thromboses were observed in group C when compared with shorter lesions (group A 2.1%, group B 1.1%, group C 3.8%; overall p = 0.29). Conclusions In a real-world setting, treatment of long coronary lesions with BVS ≥60 mm was associated with a higher TLF rate, driven by myocardial infarction and clinically driven target lesion revascularization. © 2017

U2 - 10.1016/j.jcin.2016.12.013

DO - 10.1016/j.jcin.2016.12.013

M3 - Article

VL - 10

SP - 560

EP - 568

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

SN - 1936-8798

IS - 6

ER -